Eisai Co., Ltd. (TYO:4523)

Japan flag Japan · Delayed Price · Currency is JPY
5,137.00
+125.00 (2.49%)
Sep 5, 2025, 3:30 PM JST
2.49%
Market Cap1.45T
Revenue (ttm)803.02B
Net Income (ttm)50.33B
Shares Out281.89M
EPS (ttm)178.19
PE Ratio28.83
Forward PE36.86
Dividend160.00 (3.11%)
Ex-Dividend DateSep 29, 2025
Volume2,096,300
Average Volume1,549,610
Open5,020.00
Previous Close5,012.00
Day's Range5,002.00 - 5,137.00
52-Week Range3,463.00 - 5,988.00
Beta-0.20
RSI76.96
Earnings DateNov 5, 2025

About Eisai

Eisai Co., Ltd. engages in the research and development, manufacture, sale, and import and export of pharmaceuticals in Japan. It offers Dayvigo, for the treatment of insomnia; LEQEMBI is a humanized immunoglobulin gamma 1 (IgG1); Lenvima, an anticancer agent/molecular targeted medicine for the treatment of thyroid cancer, renal cell carcinoma in combination with everolimus, and hepatocellular carcinoma; and Halaven, an anticancer agent for the treatment of breast cancer. The company also provides Methycobal for the treatment of peripheral neur... [Read more]

Sector Healthcare
Founded 1941
Employees 10,917
Stock Exchange Tokyo Stock Exchange
Ticker Symbol 4523
Full Company Profile

Financial Performance

In 2024, Eisai's revenue was 789.40 billion, an increase of 6.42% compared to the previous year's 741.75 billion. Earnings were 46.43 billion, an increase of 9.49%.

Financial Statements

News

Eisai to Present Latest Data on Lemborexant and Novel Orexin Receptor Agonist E2086 at The World Sleep 2025

TOKYO, Sept. 3, 2025 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that the company will deliver a total of 11 presentations, including clinical data...

3 days ago - PRNewsWire

Eisai Initiated Rolling Supplemental Biologics License Application to the U.S. ...

Eisai Initiated Rolling Supplemental Biologics License Application to the U.S. FDA for LEQEMBI® IQLIK™ (lecanemab-irmb) as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Diseas...

4 days ago - GuruFocus

Eisai Initiated Rolling Supplemental Biologics License Application to the U.S. FDA for LEQEMBI® IQLIK™ (lecanemab-irmb) as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease Under Fast Track Status

LEQEMBI IQLIK, if approved for initiation dosing, would be the first and only anti-amyloid treatment to offer at-home injection from the start to help patients and care partners treat this progressive...

4 days ago - Benzinga

Eisai Initiated Rolling Supplemental Biologics License Application to the U.S. FDA for LEQEMBI® IQLIK™ (lecanemab-irmb) as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease Under Fast Track Status

LEQEMBI IQLIK, if approved for initiation dosing, would be the first and only anti-amyloid treatment to offer at-home injection from the start to help patients and care partners treat this progressive...

4 days ago - PRNewsWire

US FDA approves injectable version of Eisai-Biogen's Alzheimer's drug

The U.S. Food and Drug Administration has approved an injectable version of Eisai and Biogen's Alzheimer's disease drug Leqembi, the companies said on Friday, allowing for an easier treatment option f...

8 days ago - Reuters

FDA Approves Biogen, Eisai's Highly Anticipated Alzheimer's Treatment

Biogen and Eisai won Food and Drug Administration approval of an at-home shot version of their Alzheimer's treatment Leqembi.

8 days ago - Investor's Business Daily

Biogen Inc (BIIB) and Eisai Launch Alzheimer's Drug LEQEMBI in Europe | BIIB stock news

Biogen Inc (BIIB) and Eisai Launch Alzheimer's Drug LEQEMBI in Europe | BIIB stock news

13 days ago - GuruFocus

Pres. Trump's push to lower drug prices 'is a good starting point', says Dr. Scott Gottlieb

Former FDA Commissioner Dr. Scott Gottlieb joins 'Squawk Box' to discuss news of President Trump ordering pharma companies to lower U.S. drug prices in the next 60 days, the move to tiered pricing glo...

5 weeks ago - CNBC Television

President Trump demands drugmakers slash prices within 60 days

CNBC's Joe Kernen reports on the latest news.

5 weeks ago - CNBC Television

Patients still benefit from Eisai and Biogen Alzheimer's drug after four years, study finds

Eisai and Biogen's Alzheimer's drug Leqembi continued to slow progress of the disease with no new safety issues four years into treatment, according to new data presented at a medical meeting on Wedne...

5 weeks ago - Reuters

"URECE" (Dotinurad) Launched in China as a treatment for Gout

TOKYO, July 14, 2025 - (JCN Newswire) - Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that it has launched "URECE" (brand name in China: "Youlesi", generic name: dot...

7 weeks ago - Benzinga

Eisai Co., Ltd. 2024 Q4 - Results - Earnings Call Presentation

The following slide deck was published by Eisai Co., Ltd.

4 months ago - Seeking Alpha

Europe Approves Eisai-Biogen's Alzheimer's Drug 'Under Strict Conditions' After Initial Negative Opinion

The European Commission (EC) on Tuesday approved Eisai Co., Ltd. (OTC: ESALY) and Biogen Inc.’s (NASDAQ: BIIB) amyloid-beta (Aβ) monoclonal antibody Leqembi (lecanemab) , The Commission said it gran...

5 months ago - Benzinga

EU authorizes Eisai-Biogen's drug for treatment of early Alzheimer's disease

The European Commission on Tuesday authorized the use of Eisai and Biogen's drug to treat mild cognitive impairment in the early stages of Alzheimer's disease.

5 months ago - Reuters

Japanese Stocks Rise With Market Focused on U.S. Trade News

Japan's Nikkei Stock Average closed 0.3% higher at 35725.87 as gains in the heavy industry and video game shares offset the losses in pharmaceutical and utility stocks. IHI gained 5.7% and Konami rose...

5 months ago - Barron's

LEQEMBI Market Sales Reflect Growing Confidence in Disease-Modifying Alzheimer's Treatments| DelveInsight

New York, USA, March 03, 2025 (GLOBE NEWSWIRE) -- LEQEMBI Market Sales Reflect Growing Confidence in Disease-Modifying Alzheimer's Treatments| DelveInsight LEQEMBI (lecanemab) has significant market p...

6 months ago - Benzinga